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Purpose: To examine whether small ubiquitin-like modifier 4 (SUMO4) polymorphisms were associated with Vogt-
Koyanagi-Harada (VKH) syndrome in the Chinese Han population.
Methods: Genotyping for SUMO4 polymorphisms at G-847A, A-504G, A+163G, and C+438T loci was performed on
231 VKH patients and 302 controls using polymerase chain reaction restriction fragment length polymorphism.
Results: A decreased frequency of SUMO4 +438 TT genotype was found in VKH patients compared with healthy controls
(p=0.009). However, the significance was lost after Bonferroni correction. Human leukocyte antigens (HLA)-DR4 and
HLA-DRw53  were  significantly  associated  with  susceptibility  to  VKH  syndrome  (p=3.21×10−16  and  7.08×10−5,
respectively). Stratification analysis based on HLA-DR4 and HLA-DRw53 did not show any associations between SUMO4
polymorphisms and VKH syndrome, although there was a big difference in the percentage of certain allele and genotype
frequencies between HLA-DRw53 negative patients and controls. There was no significance in clinical findings and gender
stratification analysis.
Conclusions: HLA-DR4 and HLA-DRw53 are strongly associated with the susceptibility to VKH syndrome in the Chinese
Han population. However, none of the currently known single nucleotide polymorphisms (SNPs) of SUMO4 are associated
with this syndrome.
Vogt-Koyanagi-Harada (VKH)syndrome is one of the
most common uveitis entities in China [1]. It is characterized
by a granulomatous panuveitis frequently in association with
extraocular findings such as pleocytosis in the cerebrospinal
fluid (CSF), dysacusis, alopecia, poliosis, and vitiligo [2-4].
Although the exact pathogenesis of VKH syndrome remains
unclear, numerous studies have shown that immunogenetic
factors are involved in the development of this syndrome. T
cells  autoreactive  against  tyrosinase  family  proteins  are
possibly involved in VKH syndrome. Meanwhile, genetic
factors  also  play  an  important  role  in  VKH  syndrome  as
evidenced  by  the  increased  rates  of  this  syndrome  in
pigmented groups [2], familial aggregation [5-7], and strong
association with human leukocyte antigens (HLA)-DR4 and
HLA-DRw53 in various ethnic groups including the Chinese
and Japanese [8-10]. However, little is known about the genes
that present susceptibility to the VKH syndrome except HLA
[11-13].
Recently,  studies  have  demonstrated  that  multiple
autoimmune diseases may share common susceptibility genes
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by whole genome association and family based association
studies  [14-17].  Therefore,  susceptibility  genes  associated
with other autoimmune diseases may be candidates in the
study  of  gene  susceptibility  to  VKH  syndrome,  an
autoimmune  uveitis  commonly  seen  in  China.  Small
ubiquitin-like modifier 4 (SUMO4) is located on chromosome
6p25. Recently, certain SUMO4 polymorphisms have been
shown to be clearly associated with type 1 diabetes in multiple
Asian populations [18,19] as well as with other autoimmune
diseases  [19-22],  despite  controversial  observations  in
Caucasians [18,23-25]. SUMO4 polymorphisms could also be
involved in the pathogenesis of VKH syndrome, and this
hypothesis was therefore the subject of the study presented
here.
METHODS
Subjects: Blood samples were collected from 231 Chinese
Han VKH patients (128 males and 103 females) and 302 age-
and  sex-matched,  unrelated  Chinese  Han  healthy  controls
(164 males and 138 females), which were recruited from the
Uveitis Study Center of the Zhongshan Ophthalmic Center,
Sun Yat-sen University, Guangzhou, P.R. China and The First
Affiliated  Hospital,  Chongqing  Medical  University,
Chongqing, P.R. China. The institutional ethics committee of
Zhongshan  Ophthalmic  Center,  Sun  Yat-sen  University,
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2597Guangzhou, P.R. China approved this study, and informed
consent was obtained from all tested subjects.
DNA extraction: Genomic DNA samples were extracted and
isolated from ethylene diamine tetraacetic acid (EDTA) anti-
coagulated peripheral blood mononuclear cells (PBMCs) of
VKH patients and healthy controls by a conventional salting
out method. These DNA samples were diluted in PCR grade
water and stored at −70 °C until used.
Genotyping: Polymerase chain reaction (PCR) was performed
using primers at G-847A locate (Forward, 5′-TCC CAA CCA
ATA ATA GCA AGT CT-3′; Reverse, 5′-ATG CCT GGA
TCA AAA CAC ACA-3′), A-504G locate (Forward, 5′- TGT
GTG TTT TGA TCC AGG CAT TA-3′; Reverse, 5′-TGT
TTT  GCT  CCT  CTT  TTC  CTC  TT-3′),  A+163G  locate
(Forward, 5′-ATT GTG AAC CAC GGG GAT TGT TA-3′;
Reverse,  5′-CAGCGTTCTGGAGTAAAGAAG-3′),  and  C
+438T locate (Forward, 5′-ATA CCA GTT ACT TCA TGT
ATA ATA GA-3′; Reverse, 5′-AGA TTA CTG CAT TCT
CAA  TTA  G  −3′).  PCR  products  at  G-847A  (rs237026),
A-504G  (rs600739),  A+163G  (rs237025),  and  C+438T
(rs237024) loci were incubated with SspI at 37 °C, Alw21I at
37 °C, MseI at 65 °C, and MnlI at 37 °C (MBI Fermentas,
Vilnius,  Lithuania)  for  at  least  4  h,  respectively.  PCR
fragments were separated on 3% agarose gels. Twenty percent
of the PCR samples were directly sequenced to confirm the
polymerase  chain  reaction  restriction  fragment  length
polymorphism  (PCR-RFLP)  results  (Invitrogen
Biotechnology  Co.,  Guangzhou,  China).  HLA-DR4
genotyping was performed using the PCR sequence specific
primers (SSP) method as previously described [26]. HLA-
DRw53 genotyping was performed as previously described
[27].
Statistical analysis: The χ2 test was applied to analyze the
Hardy–Weinberg equilibrium (HWE). The χ2 test or Fisher’s
exact test was performed to compare the allelic, genotypic,
and  haplotypic  distribution  between  VKH  patients  and
healthy controls using version 12.0 of SPSS for Windows
(SPSS Inc., Chicago, IL). Analysis of linkage disequilibrium
(LD) of each SNP and haplotype was performed using the
Haploview  v3.32  program  [28,29].  The  p  values  were
corrected  using  the  Bonferroni  correction  to  account  for
multiple testing. Sample sizes were estimated by Quanto 1.2
software (Department of Preventive Medicine, University of
Southern California, Los Angles, CA).
RESULTS
Descriptive data of the tested patients and controls: Detailed
clinical findings of the enrolled VKH patients are shown in
Table1. The average age of the VKH patients was 33.6±12.4
years and that of healthy controls was 35.4±12.0 years. No
statistical difference was observed between VKH patients and
controls in the distribution of age and gender (p>0.05).
Single  nucleotide  polymorphism  and  haplotype  analyses
between  polymorphisms  of  SUMO4  and  Vogt-Koyanagi-
Harada syndrome: The distribution of genotype for each SNP
including G-847A, A-504G, A+163G, and C+438T did not
deviate from the HWE in VKH patients and healthy controls
(p>0.05).  A  decreased  frequency  of  SUMO4  +438  TT
genotype  was  observed  in  VKH  patients  compared  with
healthy  controls  (p=0.009,  χ2=9.36).  However,  it  did  not
remain significant after Bonferroni correction (Table 2).
Haplotype analysis using the Haploview 3.32 software
showed that the four SNPs were in strong linkage (D’=84–
91). A decreased frequency of SUMO4 haplotype (−847A,
−504G, +163A, and +438T) was observed in VKH patients
compared with healthy controls (p=0.008, χ2=7.07). However,
the significance was lost after Bonferroni correction (Table
3).
Stratification analysis of SUMO4 polymorphisms with the
status of HLA-DR4, HLA-DRw53, the clinical findings, and
gender: Our study showed that the frequency of HLA-DR4
TABLE 1. HLA-DR4 AND HLA-DRW53 DISTRIBUTION AND CLINICAL FINDINGS OF PATIENTS WITH VKH SYNDROME.
Characteristics
  VKH Patients
HLA-DR4 + HLA-DR4 - HLA-DRw53 + HLA-DRw53 -
Number of patients (%) 179 (77.5%) 52 (22.5%) 203 (87.9%) 28 (12.1%)
Male 103 (80.5%) 25 (19.5%) 116 (90.6%) 12 (9.4%)
Female 76 (73.8%) 27 (26.2%) 87 (84.5%) 16 (15.5%)
Neck stiffness 74 (72.5%) 28 (27.5%) 89 (87.3%) 13 (12.7%)
Alopecia 26 (72.2%) 10 (27.8%) 30 (83.3%) 6 (16.7%)
Poliosis 65 (73.9%) 23 (26.1%) 78 (88.6%) 10 (11.4%)
Vitiligo 41 (74.5%) 14 (25.5%) 48 (87.3%) 7 (12.7%)
Dysacusia 57 (69.5%) 25 (30.5%) 70 (85.4%) 12 (14.6%)
Tinnitus 61 (84.7%) 11 (15.3%) 67 (93.1%) 5 (6.9%)
Scalp hypersensitivity 32 (74.4%) 11 (25.6%) 38 (88.4%) 5 (11.6%)
The age at onset (years±SD) for all VKH patients was 33.6±12.4 years.
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2598was significantly increased in 231 VKH patients as compared
with  that  in  302  healthy  controls  (77.5%  versus  19.5%,
p=3.21×10−16,  χ2=66.67,  OR=13.74,  95%  CI=6.99–26.98).
HLA-DRw53 was also shown to be significantly associated
with susceptibility to VKH syndrome in the Chinese Han
population  (87.9%  versus  63.9%,  p=7.08×10−5,  χ2=15.79,
OR=4.13, 95% CI=1.99–8.55). To test whether there was an
influence  of  HLA-DR4  and  DRw53  on  the  SUMO4
association, stratification analysis was performed according
to these parameters. The allele and genotype frequencies of
the four SNPs of SUMO4 were not different between HLA-
DR4 positive patients and HLA-DR4 positive controls and
between HLA-DR4 negative patients and HLA-DR4 negative
controls (Table 4). Similar results were also observed in HLA-
DRw53  stratification  analysis  (Table  5).  However,  a  big
difference was observed in HLA-DRw53 negative patients
compared with HLA-DRw53 negative controls (G-847A: AA
genotype,  HLA-DRw53-  patients  versus  HLA-DRw53-
controls: 40.7% versus 59.4%, AG genotype, HLA-DRw53-
patients versus HLA-DRw53- controls: 48.1% versus 31.1%;
A-504G: AA genotype, HLA-DRw53- patients versus HLA-
DRw53-  controls:  40.8%  versus  21.5%,  A  allele,  HLA-
DRw53- patients versus HLA-DRw53- controls: 59.3% versus
43.9%; A+163G: AA genotype, HLA-DRw53- patients versus
HLA-DRw53- controls: 39.3% versus 56.9%, AG genotype,
HLA-DRw53- patients versus HLA-DRw53- controls: 50.0%
versus 33.0%; Table 5).
Stratification analysis was also performed according to
clinical findings including neck stiffness, tinnitus, alopecia,
poliosis, dysacusis, scalp hypersensitivity, and vitiligo. No
association  was  found  between  the  four  SNPs  and  any
extraocular findings. The analysis of gender stratification also
showed no association of SUMO4 polymorphisms with VKH
syndrome.
DISCUSSION
In  this  study,  we  examined  the  association  of  SUMO4
polymorphisms  with  VKH  syndrome  in  the  Chinese  Han
population. Our results failed to find an association between
SUMO4  polymorphisms  and  VKH  syndrome  even  after
stratification for HLA-DR4, HLA-DRw53, clinical features,
and gender.







χ2 p value pca value OR
(95% CI)
−847 G→A GG 16 (7.1) 30 (10.1) 3.15 0.207 NSb
AG 104 (46.0) 116 (39.2)
AA 106 (46.9) 150 (50.7)
G 117 (30.1) 176 (29.7) 2.38 0.120 NS 1.0 (0.8–1.3)
A 343 (69.9) 416 (70.3)
−504 A→G AA 54 (24.0) 66 (22.2) 0.25 0.885 NS
AG 107 (47.6) 146 (49.2)
GG 64 (28.4) 85 (28.6)
A 215 (47.8) 278 (46.8) 0.10 0.754 NS 1.0 (0.8–1.3)
G 235 (52.2) 316 (53.2)
+163 A→G AA 107 (46.5) 145 (48.0) 1.05 0.591 NS
AG 107 (46.5) 130 (43.0)
GG 16 (7.0) 27 (8.9)
A 319 (69.7) 420 (69.5) 0.002 0.968 NS 1.0 (0.8–1.3)
G 139 (30.3) 184 (30.5)
+438 C→T CC 107 (46.7) 135 (44.7) 9.36 0.009 NS
CT 107 (46.7) 122 (40.4)
TT 15 (6.6) 45 (14.9)
C 320 (70.2) 392 (64.9) 3.18 0.075 NS 1.3 (1.0–1.6)
T 136 (29.8) 212 (35.1)
a Bonferroni corrected p value; bNot significant.





χ2 p value pca value OR
(95% CI)
AGAC 228.2 (49.8) 274.6 (45.5) 1.99 0.158 NSb 1.2 (0.9–1.5)
GAGT 126.4 (27.6) 156.3 (25.9) 0.40 0.529 NS 1.1 (0.8–1.4)
AAAC 79.1 (17.3) 101.5 (16.8) 0.04 0.839 NS 1.0 (0.8–1.5)
AGAT 4.8 (1.0) 21.9 (3.6) 7.07 0.008 NS 0.2 (0.06–0.4)
a Bonferroni corrected p value; bNot significant.
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2599SUMO4 has been shown to be involved in the regulation
of NF-кB, an important transcription factor in autoimmune
diseases.  It  has  been  reported  that  the  SUMO4  A+163G
(M55V)  polymorphism  is  an  essential  polymorphism
involved in regulating its own sumoylation, and it has been
shown to be associated with certain autoimmune diseases such
as  type  1  diabetes,  autoimmune  thyroid  disease,  and
rheumatoid arthritis without amyloidosis [19]. These results
suggest that this polymorphism could be a susceptibility gene
shared by certain autoimmune diseases, although conflicting
data have been reported in Sjögren’s syndrome [19]. The
identification  of  a  general  susceptibility  gene  for  several
autoimmune diseases could make an important contribution
to the understanding of the pathogenesis and modulation of
these diseases. The question was therefore raised whether the
SUMO4 A+163G polymorphism was also associated with
VKH syndrome. This study was designed to clarify this issue.
We strictly chose the patients who were definitely diagnosed
with VKH syndrome according to the revised criteria [30] to
exclude the influence of misdiagnosis. As ethnic confounding
could  also  influence  the  association  results,  only  VKH
patients with Chinese Han nationality as well as age- and sex-
matched controls with the same nationality were enrolled in
this study. The frequency of the +163G allele in the control
population presented in our study is similar with that in the
Chinese  population  reported  by  Li  et  al.  [31]  and  in  the
Japanese population reported by Noso et al. [20]. Meanwhile,
a power analysis of the study population showed that our
sample size was large enough to detect a possible association.
Unexpectedly, we failed to find an association of the SUMO4
A+163G polymorphism with VKH syndrome. This suggests
that  this  polymorphism  may  not  be  involved  in  the
development of susceptibility to VKH syndrome.
Others SNPs including G-847A, A-504G, and C+438T
polymorphisms have been identified by direct sequencing of
the whole SUMO4 gene in the Japanese population [20,32].
Our previous results showed an association of SUMO4 C
+438T  polymorphism  with  Behcet’s  disease  [22],  another
common uveitis entity observed in China. The present study
also failed to show any association of the SUMO4 G-847A,
A-504G, and C+438T polymorphisms with VKH syndrome.
This difference may result from the different features of these
two uveitis entities. One of the striking features of Behcet’s
disease is its characteristic non-granulomatous inflammation
while VKH syndrome is in fact a granulomatous inflammation
[33].
Like HLA-DR4, HLA-DRw53 have been demonstrated to
be  strongly  associated  with  VKH  syndrome.  Therefore,
genotyping of HLA-DR4 and HLA-DRw53 was performed.
The association of HLA-DR4 and HLA-DRw53 with VKH
syndrome was extremely strong in this study. The results were
generally consistent with those previously reported in Chinese
[4,8,34] and Spanish patients [35]. Furthermore, stratification
analysis according to HLA-DR4 and HLA-DRw53 did not
show any association of SUMO4 with VKH syndrome in our
study. This result is consistent with the previous studies that
TABLE 4. STRATIFICATION ANALYSIS FOR HLA-DR4 AND SUMO4 POLYMORPHISMS AND THE COMPARISON OF FREQUENCIES OF SUMO4 ALLELE AND GENOTYPE IN HLA-DR4+

















−847G→A GG 12 (6.8) 10 (17.2) 0.041 NSb 4 (8.0) 20(8.4) 0.757 NS
AG                       81 (46.0)                 20 (34.5)     23 (46.0) 96 (40.3)
AA                       83 (47.2) 28 (48.3)     23 (46.0) 122 (51.3)
G         105 (29.8) 40 (34.5) 0.347 NS      31 (31.0) 136 (28.6) 0.627             NS
A         247 (70.2) 76 (65.5)     69 (69.0) 340 (71.4)
−504A→G AA 40 (22.9) 11 (19.0) 0.656 NS 14 (28.0) 55 (23.0) 0.696             NS
AG         85 (48.6) 27 (46.6)     22 (44.0) 119 (49.8)
GG        50 (28.6) 20 (34.5)     14 (28.0) 65 (27.2)
A        165 (47.1) 49 (42.2) 0.359 NS      50 (50.0) 249 (52.1) 0.703               NS
G        185 (52.9) 67 (57.8)           50 (50.0) 229 (47.9)
+163A→G AA 84 (46.9) 29 (49.2) 0.820 NS 23 (45.1) 116 (47.7) 0.872             NS
AG        83 (46.4) 25 (42.4)           24 (47.1) 105 (43.2)
GG       12 (6.7) 5 (8.5)           4 (7.8) 22 (9.1)
A        251 (70.1) 83 (70.3) 0.963 NS      70 (68.6) 337 (69.3)   0.887             NS
G        107 (29.9) 35 (29.7)            32 (31.4) 149 (30.7)
+438C→T CC 82 (46.3) 29 (49.2) 0.089 NS 25 (48.1) 106 (43.6) 0.562             NS
CT        85 (48.0) 22 (37.3)          22 (42.3) 100 (41.2)
TT      10 (5.6) 8 (13.6)          5 (9.6) 37 (15.2)
C       249 (70.3) 80 (67.8) 0.603 NS     72 (69.2) 312 (64.2)  0.328             NS
T       105 (29.7) 38 (32.2)           32 (30.8) 174 (35.8)
a Bonferroni corrected p value; bNot significant.
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2600SUMO4 M55V polymorphism was independent of the HLA
class  II  haplotype  [19,32],  which  is  located  on  the  same
chromosome 6 as SUMO4.
It is worthy to point out that there was a big difference in
the  percentages  of  certain  alleles  and  genotypes  between
HLA-DRw53  negative  patients  and  controls,  although  the
difference did not reach statistical significance. As the sample
size  of  HLA-DRw53  negative  is  small  (28  patients),  it  is
necessary  to  further  test  the  association  of  SUMO4
polymorphisms  with  HLA-DRw53  negative  patients  using
larger samples.
In  conclusion,  we  failed  to  detect  an  association  of
SUMO4 polymorphisms with VKH syndrome in Chinese Han
population. In agreement with earlier studies, we found a
strong  association  of  HLA-DR4  and  HLA-DRw53  with
susceptibility  to  VKH  syndrome.  A  big  but  insignificant
difference of allele and genotype frequency was noted in HLA-
DRw53 negative patients when compared with HLA-DRw53
negative controls. Further studies are necessary to elucidate
the  association  of  SUMO4  polymorphisms  with  VKH
syndrome in a HLA-DRw53 negative population using larger
samples.
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